Biogenesis Bago
Biogénesis Bagó is an Argentine animal health biotechnology company that develops, manufactures, and commercializes FMD and rabies vaccines, pharmaceuticals, reproductive hormones, and nutraceuticals for livestock and companion animals across 60+ countries.
- Company typePrivate
- Founded2000
- HeadquartersGarín, Argentina
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biogenesis Bago does
Biogénesis Bagó S.A. is an Argentine-domiciled animal health biotechnology company that develops, manufactures, and commercializes vaccines, pharmaceuticals, reproductive hormones, and nutraceuticals for livestock and companion animals across more than 60 countries. The company is the largest veterinary vaccine producer in Latin America and the fifth-largest globally in pet vaccine production capacity, anchored by its proprietary BIOAFTOGEN® foot-and-mouth disease (FMD) vaccine — the first product worldwide to obtain prequalification from the European Commission for the Control of Foot-and-Mouth Disease (EuFMD/FAO) — and a high-potency SAT 1/SAT 2/SAT 3 FMD vaccine line. Its core technical differentiator is a liquid-nitrogen cryopreservation system for concentrated viral antigens (described as unique in Latin America for animal health) that enables emergency vaccine production within 5–6 days versus the industry standard of roughly three months, making the company a designated operator of national antigen and vaccine banks for Argentina (SENASA, since 2000), the United States and Canada (USDA North American FMD Vaccine Bank, since 2006), Taiwan, South Korea, and now Brazil (via Tecpar, 2025). Beyond FMD, the company supplies more than 140 million doses of canine rabies vaccine to 15 countries via the Pan American Health Organization Revolving Fund, and operates a 200+ product pet health portfolio assembled through the acquisitions of Laboratorio Mayors (2022), HIPRA's reproduction hormone line (Gestavet family, 2022), and Mundo Animal (January 2025).
The company's business model is a hybrid of direct enterprise sales to government animal-health authorities and large livestock producers, channel partnerships with local veterinary distributors, and licensing/royalty revenue from technology-transfer arrangements that build local FMD and rabies vaccine manufacturing capacity in countries including Brazil, Saudi Arabia, and South Korea. Recurring revenue is generated through multi-year antigen and vaccine bank contracts, with notable anchor agreements including a 10-year Brazil arrangement covering 10 million antigen doses plus an immediate 10 million-dose vaccine supply. The operating footprint comprises seven production plants across Argentina, Brazil, China, South Korea, and Saudi Arabia, supported by 12 commercial offices in Latin America, Europe, Asia, and the Middle East; total headcount exceeds 1,300 across an interdisciplinary multinational team. Biogénesis Bagó is a subsidiary of the Argentine Bagó Group and discloses no external equity funding rounds, suggesting the recent acquisition-led expansion (seven transactions over five years) has been financed through parent-group balance sheet capacity and operating cash flow. The company's stated objective is to rank among the top 20 global animal health companies by 2026.
Biogenesis Bago firmographics
Firmographics- Name
- Biogenesis Bago
- Legal name
- BIOGÉNESIS BAGÓ S.A.
- Website
- https://biogenesisbago.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Biogénesis Bagó is an Argentine animal health biotechnology company that develops, manufactures, and commercializes FMD and rabies vaccines, pharmaceuticals, reproductive hormones, and nutraceuticals for livestock and companion animals across 60+ countries.
- Ownership category
- akta.pro rank
Biogenesis Bago industry classification
Industry- Product category
- Veterinary Biologics and Animal Health Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Veterinary Vaccines (Biologics) (HLAMAEAL)
- akta.pro secondary industries
- Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Biogenesis Bago is headquartered
LocationHeadquarters
- HQ city
- Garín
- HQ country
- Argentina
- HQ region
- Latin America
Offices17 records
Markets served
Biogenesis Bago business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Vaccine Sales: Sale of foot-and-mouth disease vaccines, rabies vaccines, and companion animal vaccines to governments, distributors, and veterinary practices across 60+ countries. Major supplier to Pan American Health Organization for rabies vaccines.
- Pharmaceutical and Antiparasitic Products: Sale of pharmaceutical products including antibiotics, anti-parasitics, anti-arthritic, gastric protectors, dermatological solutions, vitamins, and minerals for livestock and companion animals.
- Reproductive Hormone Products: Sale of hormone products and solutions for animal reproduction including Gestavet product line, FTAI hormones, and reproductive technologies for cattle, swine, and small ruminants.
- Technology Transfer Services: Technology transfer services for construction of FMD vaccine manufacturing sites (Saudi Arabia, South Korea) and rabies vaccine production (Brazil via Tecpar), including training and know-how licensing.
- Antigen Bank Supply Contracts: Long-term supply contracts for national antigen and vaccine banks including Brazil (10-year agreement for 10 million doses), USA, Canada, Taiwan, and South Korea, providing recurring revenue from strategic government partnerships.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
Biogenesis Bago product offering
Product offeringCore offering
Biogénesis Bagó researches, develops, manufactures, and commercializes veterinary biologics and pharmaceuticals for livestock and companion animals. Its core offering centers on foot-and-mouth disease (FMD) vaccines, rabies vaccines, antiparasitics, reproductive hormones, antibiotics, and nutraceuticals, supported by proprietary antigen cryopreservation technology enabling emergency vaccine production. The company also provides technology transfer services and supplies strategic antigen banks to governments across multiple continents.
Product overview
Biogénesis Bagó is a global biotechnology company offering a comprehensive portfolio of animal health products and services for livestock and companion animals. The product portfolio includes core vaccine products (BIOAFTOGEN FMD vaccines, rabies vaccines), pharmaceutical products (antibiotics, anti-parasitics, anti-arthritics, dermatological solutions, gastric protectors), reproductive solutions (Gestavet hormone product line), and supplements. The company operates through multiple production facilities across Argentina, Brazil, China, and other countries, with products distributed across 60+ countries in the Americas, Asia, Europe, Middle East, and North Africa. Recent acquisitions (Mayors Laboratory, Mundo Animal, HIPRA reproduction products) have expanded the portfolio to over 200 pet care solutions. Key products include BIOAFTOGEN (FMD vaccine prequalified by EuFMD/FAO), rabies vaccines (supplied to Pan American Health Organization), Gestavet reproductive hormones, and various pharmaceutical and antiparasitic products.
Differentiator
Problem solved
Functional benefit
Brands
- Gestavet: Hormonal products for animal reproduction including Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser and Esponjavet
- BIOAFTOGEN
- AFTOGEN OLEO
- BioVademécum
Products and services
- BIOAFTOGEN Foot-and-mouth disease vaccine, first in the world to obtain prequalification from EuFMD (European Commission for the Control of FMD). Provides protection for cattle, buffaloes, goats, sheep, and pigs, exported in nine formulations to 27 countries.
- Rabies Vaccine High-quality rabies vaccine for dogs and cats. Biogénesis Bagó is the main supplier of canine rabies vaccine to the Pan American Health Organization, having supplied over 140 million doses to 15 countries since 2012.
- AFTOGEN OLEO High-potency FMD vaccine for quick and long-lasting immunity across species, used for outbreak control including Indonesia (2022).
- Gestavet Product Line Complete line of hormone products for animal reproduction including Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser, and Esponjavet. Covers cattle, swine, and small ruminants reproduction solutions, acquired from HIPRA.
- Antiparasitics Anti-parasitic products for livestock and companion animals.
- Pharmaceuticals Pharmaceutical products including antibiotics (beta-lactams), gastric protectors, and anti-arthritic treatments for animals.
- Supplements and Nutraceuticals Vitamin, mineral, and nutritional supplement products for animals.
- Reproductive Products Hormone products for animal reproduction including FTAI (Fixed Time Artificial Insemination) hormones and reproductive solutions.
- Mayors Laboratory Products Pharmaceutical products for companion animals including anti-arthritic, anti-parasiticides, gastric protectors, and dermatological solutions. Products sold in 16 countries in Latin America and Middle East, acquired from Mayors Laboratory.
- Mundo Animal Products Solutions for pet nutrition, medicine, and hygiene developed at manufacturing site in Pindamonhangaba, São Paulo, Brazil. Complements existing portfolio creating over 200 solutions for the pet segment globally, acquired from Mundo Animal.
- Live Attenuated Virus (MLV) Vaccines MLV vaccines for companion animals and livestock including 3-in-1, 5-in-1/6-in-1 vaccines for cats. Produced at Campo Largo Brazil facility with annual capacity over 10 million doses.
- Hygiene and Skin Health Products Products for hygiene and skin health care for animals.
Quantifiable outcome
- Emergency FMD vaccine production in 5-6 days using cryopreserved antigen bank technology
- +4 more outcomes
Companies that use Biogenesis Bago
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Biogenesis Bago technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Biogenesis Bago partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Government of South AfricacoreSupply agreement for 1 million initial FMD vaccine doses (with additional 5 million pending regulatory approval) against SAT 1, SAT 2, and SAT 3 strains. Vaccines integrated into massive national vaccination campaign targeting 80%+ coverage of 14 million cattle.
- Botswana Vaccine InstituteminorGovernment of South Africa sourced 2 million vaccines from Botswana Vaccine Institute as part of coordinated national vaccination strategy.
- Paraná Technological Institute (Tecpar)coreTechnology transfer agreement for creation of Brazil's first national FMD antigen and vaccine bank; Biogénesis Bagó supplies antigens while Tecpar formulates and distributes emergency vaccines nationwide within 72 hours. 10-year agreement covering 10 million doses of antigens from two FMD serotypes plus immediate supply of up to 10 million vaccine doses.
- ElancominorPartnership for FMD vaccine (Bioaftogen) launch in Indonesian market.
- CVG Tech and Advance PharmaminorPartnership for FMD vaccine (Bioaftogen) launch in Thai market.
- Arab Centre for Studies of Arid Zones and Dry Lands (ACSAD)minorMemorandum of Understanding signed to collaborate on improving livestock productivity across the Middle East, leveraging Biogénesis Bagó's FMD expertise.
- Fundación Mundo SanominorCollaboration on rabies vaccination campaigns across Argentina; joint public health initiatives to address rabies as a preventable disease.
- Global Alliance for Rabies ControlminorSupporting the 'End Rabies Now' campaign and related actions as part of FAO-OIE-WHO initiative.
- TECPAR (Brazil)coreTechnology transfer agreement for rabies vaccine production in Brazil, first technology transfer project of its kind in the country.
- HIPRA (Spain)coreAcquisition of complete portfolio of hormone products for animal reproduction including brands Gestavet, Gestavet Prost, Gestavet GnRH, Gonaser, and Esponjavet. Enables entry into European market and 30 new countries; positions Biogénesis Bagó as global leader in reproduction for cattle, swine, and small ruminants.
Scale indicators14 records
Recent moves6 records
Expansion highlights7 records
Biogenesis Bago competitors and assessment
Company assessmentDirect peers
- Ceva Santé Animale: France-based global animal health company focused on vaccines, pharmaceuticals, and biologicals for livestock and companion animals. Closely comparable mid-sized competitor with similar geographic reach and vaccine-led business model.
- HIPRA: Spanish animal health biotechnology company specializing in veterinary vaccines and pharmaceuticals for livestock and companion animals. Direct competitor in the FMD and reproductive hormone segments and historically a counterpart whose product line Biogénesis Bagó partially acquired.
- Botswana Vaccine Institute: African veterinary vaccine manufacturer specializing in FMD and livestock vaccines for SAT strains. Directly comparable as an FMD-focused player; referenced in source data as a competing supplier for the South Africa vaccination campaign.
Others
- Elanco Animal Health: Global animal health company with a strong livestock vaccine and therapeutic portfolio. Already a distribution partner of Biogénesis Bagó for the Bioaftogen launch in Indonesia and a competitor in broader FMD and companion animal categories.
Broad incumbents
- Virbac: France-based global animal health company focused on vaccines, parasiticides, and pharmaceuticals for livestock and companion animals. Comparable breadth in companion animal and livestock segments and a competitor in Latin American pet health markets.
- Vetoquinol: France-based global animal health company with a portfolio of pharmaceuticals and biologicals for livestock and pets. Comparable as a mid-sized European-rooted animal health company competing in pet pharma and livestock therapeutic categories.
- MSD Animal Health (Merck Animal Health): Global animal health division of Merck offering vaccines, anti-infectives, and parasiticides for livestock and companion animals. Competes in the FMD vaccine category globally and is a reference point for the scale Biogénesis Bagó is targeting.
- Zoetis: Global leader in animal health medicines, vaccines, and diagnostics, with a portfolio covering livestock and companion animals. Operates broadly across the same vaccine and pharmaceutical categories as Biogénesis Bagó but at vastly larger scale; key competitor for government tenders.
- Boehringer Ingelheim Animal Health: One of the top global animal health companies with a comprehensive vaccine, parasiticide, and therapeutics portfolio for livestock and pets. Competes with Biogénesis Bagó in FMD vaccines and broader veterinary biologics categories, particularly in Latin America.
Emerging players
- Indian Immunologicals: India-based veterinary vaccine manufacturer with a portfolio spanning livestock and companion animal vaccines, including FMD. Comparable as an emerging-market, vaccine-focused animal health company with government-tender exposure in its home region.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Biogenesis Bago social profiles
Digital presenceBiogenesis Bago compliance and trust
Trust signalCompliance1 record
Biogenesis Bago financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biogenesis Bago leadership team
Management profileNumber of profiles
Profiles4 records
Biogenesis Bago subsidiaries and ownership
Company hierarchySubsidiaries4 records
Biogenesis Bago funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biogenesis Bago M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biogenesis Bago
What does Biogenesis Bago do?
Biogénesis Bagó researches, develops, manufactures, and commercializes veterinary biologics and pharmaceuticals for livestock and companion animals. Its core offering centers on foot-and-mouth disease (FMD) vaccines, rabies vaccines, antiparasitics, reproductive hormones, antibiotics, and nutraceuticals, supported by proprietary antigen cryopreservation technology enabling emergency vaccine production. The company also provides technology transfer services and supplies strategic antigen banks to governments across multiple continents.
Is Biogenesis Bago a public or private company?
Biogenesis Bago is a private company. It is classified as corporate owned and is currently operating.
When was Biogenesis Bago founded?
Biogenesis Bago was founded in 2000. It employs 501 to 1,000 people.
Where is Biogenesis Bago based?
Biogenesis Bago is headquartered in Garín, Argentina, in the Latin America region.
How does Biogenesis Bago make money?
Five revenue lines are on record. Vaccine Sales are the primary driver. The others are pharmaceutical and Antiparasitic Products, reproductive Hormone Products, technology Transfer Services and antigen Bank Supply Contracts.
Who are Biogenesis Bago's main competitors?
Direct peers on record are Ceva Santé Animale, HIPRA and Botswana Vaccine Institute. Elanco Animal Health is listed as an others. Broad incumbents are Virbac, Vetoquinol, MSD Animal Health (Merck Animal Health), Zoetis and Boehringer Ingelheim Animal Health. Indian Immunologicals is listed as an emerging player.
Does Biogenesis Bago have an API?
No public API is recorded for Biogenesis Bago.
What industry is Biogenesis Bago in?
Biogenesis Bago's product category is Veterinary Biologics and Animal Health Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAI, Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO). Its NAICS code is 325414 and its SIC code is 2836.